康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00867 康哲药业

未开盘 09-03 16:08:21

11.080

+0.100

+0.91%

最高11.300	最低10.970	成交量450.10万
今开11.300	昨收10.980	日振幅3.01%
总市值269.58亿	流通市值269.58亿	总股本24.33亿
成交额4,979万	换手率0.18%	流通股本24.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00867","market":"HK","secType":"STK","nameCN":"康哲药业","latestPrice":11.08,"timestamp":1788422901000,"preClose":10.98,"halted":0,"volume":4501000,"delay":0,"changeRate":0.009107468123861534,"floatShares":2433000000,"shares":2433000000,"eps":0.7182489137678262,"marketStatus":"未开盘","change":0.1,"latestTime":"09-03 16:08:21","open":11.3,"high":11.3,"low":10.97,"amount":49790085,"amplitude":0.030055,"askPrice":11.08,"askSize":30000,"bidPrice":11.07,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":0.7396271480113836,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788485400000},"marketStatusCode":0,"adr":0,"listingDate":1285603200000,"exchange":"SEHK","adjPreClose":10.98,"dividendRate":0.031029,"openAndCloseTimeList":[[1788399000000,1788408000000],[1788411600000,1788422400000]],"volumeRatio":0.803616,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00867","defaultTab":"news","newsList":[{"id":"1160594925","title":"康哲药业子公司德镁医药获批百卢妥®治疗特应性皮炎新适应症 拓展皮肤健康版图","url":"https://stock-news.laohu8.com/highlight/detail?id=1160594925","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160594925?lang=zh_cn&edition=full","pubTime":"2026-09-03 18:02","pubTimestamp":1788429722,"startTime":"0","endTime":"0","summary":"2026年9月3日，康哲药业发布自愿性及业务进展公告称，其旗下聚焦皮肤健康的子公司德镁医药有限公司已于2026年9月2日收到中国国家药品监督管理局批准，磷酸鲁可替尼乳膏“百卢妥”轻中度特应性皮炎新药上市许可申请获批，并于2026年9月3日取得药品注册证书。该产品适用于其他外用药控制不佳或不建议使用时，2岁及以上非免疫功能受损的儿童及成人轻中度AD患者的局部短期和非持续性慢性治疗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177316058","title":"康哲药业：德维康产品Lumirix获国家药监局批准，用于特应性皮炎治疗（2026年9月2日）","url":"https://stock-news.laohu8.com/highlight/detail?id=1177316058","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177316058?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:56","pubTimestamp":1788429369,"startTime":"0","endTime":"0","summary":"2026年9月2日，康哲药业旗下德维康所提交的Lumirix新药申请，已正式获得国家药品监督管理局的批准，该药物适应症为特应性皮炎。这一获批标志着该产品在相关治疗领域迈出关键一步，为临床提供了新的选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNP33.GBP","SG9999004220.SGD","BK1191","SG9999015978.USD","00867","LU2488822045.USD","SG9999015986.USD","BK1593","IE00BMCWC346.EUR","IE00BVYPNQ40.USD","IE00BYV24P56.USD","SG9999015952.SGD","IE00BGHQDM52.EUR","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147031999","title":"康哲药业8月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1147031999","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147031999?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:27","pubTimestamp":1788254848,"startTime":"0","endTime":"0","summary":"中国时间2026年9月1日，康哲药业发布2026年8月股份变动月报表。公告显示，截至2026年8月31日，公司法定/注册股本总数维持在20,000,000,000股，每股面值USD 0.005，总额为USD 100,000,000，未发生任何增加或减少。根据公告，康哲药业普通股于8月底的已发行股份数为2,433,131,512股，库存股份数量为6,397,000股，合计2,439,528,512股。截至报告期末，公司股本总数保持稳定。康哲药业表示，相关证券发行业务及库存股份处置均遵循香港联交所《上市规则》及适用法律法规的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662677388","title":"【券商聚焦】中信建投维持康哲药业（00867）买入评级 指集采影响出清","url":"https://stock-news.laohu8.com/highlight/detail?id=2662677388","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662677388?lang=zh_cn&edition=full","pubTime":"2026-08-27 13:45","pubTimestamp":1787809531,"startTime":"0","endTime":"0","summary":"中信建投预计康哲药业2026–2028年营收为96.5亿元、114.2亿元、137.1亿元，同比增长17.5%、18.4%、20.0%；归母净利润为19.8亿元、23.8亿元、28.8亿元，同比增长33.3%、19.9%、21.1%，对应PE为14.2倍、11.8倍、9.8倍，维持“买入”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989665","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660239417","title":"高盛：下调康哲药业(00867.HK)目标价至17.96港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2660239417","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660239417?lang=zh_cn&edition=full","pubTime":"2026-08-19 14:24","pubTimestamp":1787120679,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999015978.USD","BK1593","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","SG9999015945.SGD","IE00BVYPNP33.GBP","00867","SG9999015952.SGD","SG9999015986.USD","IE00BVYPNQ40.USD","BK1191","SG9999004220.SGD","LU2488822045.USD","IE00BYV24P56.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196540415","title":"康哲药业控股有限公司（00867）修订中期股息 每股派0.1634元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1196540415","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196540415?lang=zh_cn&edition=full","pubTime":"2026-08-18 12:15","pubTimestamp":1787026527,"startTime":"0","endTime":"0","summary":"2026年8月17日，康哲药业控股有限公司（股票代码：00867）发布修订公告，更新截至2026年6月30日止六个月的中期股息安排。 根据公告，公司将派发普通中期股息每股0.1634元人民币，折合每股0.189港元，适用汇率为1人民币兑1.1561港元。  \n  \n除净日为2026年8月28日。股东若需符合派息资格，须于2026年8月31日16:30前递交股份过户文件。公司股份过户登记册将于2026年9月1日暂停办理过户手续，并于同日确定股权登记日。  \n  \n中期股息的支付日期定为2026年9月8日。公告称，本次为更新公告，原因系对宣派股息作出修订。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660345573","title":"康哲药业：上半年营业额增长12.5%至45.01亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660345573","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660345573?lang=zh_cn&edition=full","pubTime":"2026-08-18 09:45","pubTimestamp":1787017500,"startTime":"0","endTime":"0","summary":"8月17日，康哲药业（00867）发布截至2026年6月30日止六个月之中期业绩公告。报告期内，公司营业额同比增长12.5%至45.01亿元，若全按药品销售收入计算则营业额同比增长14.4%至53.41亿元。毛利同比增长11.4%至32.21亿元，毛利率为71.6%。期间溢利同比增长4.3%至9.72亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608183844237558.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608183844237558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","IE00BMCWC346.EUR","SG9999015952.SGD","IE00BGHQDM52.EUR","IE00BYV24P56.USD","SG9999015978.USD","IE00BVYPNQ40.USD","LU2488822045.USD","SG9999004220.SGD","IE00BVYPNP33.GBP","SG9999015986.USD","SG9999015945.SGD","BK1593","00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150576646","title":"康哲药业（00867）公布2026财年中期每股派息0.1643元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1150576646","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150576646?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:31","pubTimestamp":1786973484,"startTime":"0","endTime":"0","summary":"2026年8月17日，康哲药业发布公告称，将就截至2026年6月30日止六个月派发中期股息。公告显示，股息性质为普通股息，财政年度结算日为2026年12月31日。截至公告日，公司董事会成员包括执行董事林刚、陈燕玲，以及独立非执行董事梁创顺、罗瑩、馮征和李贤良。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660382734","title":"康哲药业(00867.HK)将于9月8日派发中期股息每股0.189港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660382734","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660382734?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:30","pubTimestamp":1786973419,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BMCWC346.EUR","BK1191","IE00BGHQDM52.EUR","SG9999015978.USD","SG9999015986.USD","00867","IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","SG9999004220.SGD","SG9999015952.SGD","LU2488822045.USD","SG9999015945.SGD","BK1593","IE00BYV24P56.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660497438","title":"康哲药业(00867)公布中期业绩 公司拥有人应占溢利同比增长4.77%至9.86亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660497438","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660497438?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:28","pubTimestamp":1786973287,"startTime":"0","endTime":"0","summary":"康哲药业(00867)公布2026年中期业绩，营业额同比增长 12.5%至约45亿元，毛利同比增长 11.4%至约32.21亿元，期间溢利同比增长 \n4.3%至9.715亿元，公司拥有人应占溢利同比增长4.77%至9.86亿元，每股基本盈利0.4075 元，中期股息每股0.1634元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggaonew/ganggugongg15.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggaonew/ganggugongg15.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康哲药业(00867)公布中期业绩 公司拥有人应占溢利同比增长4.77%至9.86亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE00BYV24P56.USD","SG9999004220.SGD","SG9999015978.USD","IE00BVYPNQ40.USD","IE00BMCWC346.EUR","SG9999015986.USD","LU2488822045.USD","BK1593","00867","SG9999015945.SGD","BK1191","IE00BVYPNP33.GBP","SG9999015952.SGD","IE00BGHQDM52.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142520066","title":"康哲药业（00867）上半年营收增长12.5%，创收45.01亿元 三款创新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1142520066","media":"公告速递","labels":["productRelease","dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142520066?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:25","pubTimestamp":1786973150,"startTime":"0","endTime":"0","summary":"2026年8月17日，China Medical System Holdings Limited公布截至2026年6月30日的未经审计中期业绩。期内，公司核心财务与业务数据如下：。—— 营业额45.01亿元，同比增长12.5%；若全按药品销售收入计算为53.41亿元，同比增长14.4%。—— 期间溢利9.72亿元，同比增长4.3%。—— 基本每股收益0.4075元，同比增长4.7%。—— 皮肤健康线：7.93亿元，同比增长59.1%，占比14.8%。—— 行政费用4.40亿元，同比增长2.1%，占营业额比9.8%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140641131","title":"康哲药业（00867）宣布8月17日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1140641131","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140641131?lang=zh_cn&edition=full","pubTime":"2026-08-05 18:00","pubTimestamp":1785924041,"startTime":"0","endTime":"0","summary":"康哲药业（00867）8月5日在港交所发布公告称，公司董事会将于2026年8月17日（星期一）召开会议，主要议程包括：1）审议并拟批准公司及附属公司截至2026年6月30日止六个月的中期业绩；2）考虑是否派发中期股息（如有）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123123436","title":"康哲药业更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1123123436","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123123436?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:08","pubTimestamp":1785755296,"startTime":"0","endTime":"0","summary":"康哲药业于2026年8月3日披露2026年7月股份变动月报表。公告显示，公司法定注册股本为20,000,000,000股普通股，每股面值0.005美元，法定/注册股本总额保持在100,000,000美元，报告期内无新增或减少。公司确认截至报告期末，其公眾持股量满足香港联交所相关规定。截至7月31日，公司股本整体保持稳定，未有任何发行或回购活动。公司同时声明，所有已完成的股份变动手续均遵守了香港联交所《上市规则》及相关法律规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651457047","title":"康哲药业：创新药CMS-D017临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651457047","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651457047?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:17","pubTimestamp":1784114220,"startTime":"0","endTime":"0","summary":"7月15日，康哲药业（00867）发布公告，自主研发的创新药补体因子B抑制剂CMS-D017获得中国国家药品监督管理局签发的药物临床试验批准通知书。该产品旨在治疗年龄相关性黄斑变性（AMD），NMPA同意开展临床试验以评估其安全性和有效性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607153807630490.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807630490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999015986.USD","LU0661504455.SGD","BK4208","LU0553294199.USD","BK1574","IE00BVYPNQ40.USD","06978","LU2500361329.USD","LU2637428348.USD","BK4585","SG9999015945.SGD","LU2488822045.USD","00867","LU1003077747.HKD","LU2346227817.USD","BK1191","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","LU0949170772.SGD","SG9999004220.SGD","BK1593","BK4588","LU1894683264.USD","IBBQ","IE00BMCWC346.EUR","IE00BYV24P56.USD","BK1161","LU0738911758.USD","BMED","CMS","159992","SG9999015978.USD","MEDX","SG9999015952.SGD","LU1894683348.USD","LU0545039389.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180483086","title":"康哲药业获批开展补体因子B抑制剂CMS-D017针对AMD的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1180483086","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180483086?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:35","pubTimestamp":1784111737,"startTime":"0","endTime":"0","summary":"2026年7月15日，康哲药业公告称，其自主研发的口服小分子补体因子B抑制剂CMS-D017胶囊已获国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展针对年龄相关性黄斑变性的安全性与有效性临床研究。CMS-D017采用口服给药，有望提供新的治疗选择。此前，CMS-D017已于2026年1月30日和2月3日分别获得针对阵发性睡眠性血红蛋白尿症和补体参与介导的肾脏疾病的临床试验批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103161322","title":"康哲药业：国家药监局批准CMS-D017用于年龄相关性黄斑变性的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1103161322","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103161322?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:35","pubTimestamp":1784111720,"startTime":"0","endTime":"0","summary":"中国医药系统控股有限公司宣布，其创新药物CMS-D017已获得国家药品监督管理局的批准，将开展针对年龄相关性黄斑变性的临床试验。这一进展标志着该药物在研发进程中迈出了关键一步，有望为相关眼疾患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","00867","SG9999004220.SGD","SG9999015945.SGD","IE00BVYPNQ40.USD","BK1191","SG9999015978.USD","IE00BVYPNP33.GBP","IE00BMCWC346.EUR","SG9999015986.USD","IE00BYV24P56.USD","LU2488822045.USD","IE00BGHQDM52.EUR","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162210","title":"英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162210","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651162210?lang=zh_cn&edition=full","pubTime":"2026-07-13 10:02","pubTimestamp":1783908120,"startTime":"0","endTime":"0","summary":"　　英硅智能早盘涨超7%，截至发稿，股价上涨6.21%，报45.48港元，成交额3.32亿港元。　　7月13日，据英硅智能官微消息，公司宣布与康哲药业在中枢神经系统领域开展另一项AI驱动的药物发现合作。　　根据合作协议，双方将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，双方共同推进该研发项目的合作开发。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9058117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1593","WRND","IE00BVYPNP33.GBP","BK4585","SG9999015952.SGD","IE00BVYPNQ40.USD","PBE","GSKH","BK4588","AIPO","QTOC","BBP","LFSC","LU2488822045.USD","IE00BMCWC346.EUR","GDOC","SG9999015945.SGD","SG9999015986.USD","00867","VTHR","AGIX","IE00BYV24P56.USD","BK1191","ARTY","IE00BGHQDM52.EUR","IBB","SG9999015978.USD","SBIO","SG9999004220.SGD","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651629631","title":"港股异动 | 英硅智能(03696.HK)早盘涨超7% 与康哲药业在中枢神经系统领域开展AI驱动药物发现合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651629631","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651629631?lang=zh_cn&edition=full","pubTime":"2026-07-13 09:43","pubTimestamp":1783907005,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999015986.USD","SG9999015978.USD","BK1141","IE00BVYPNQ40.USD","LU2488822045.USD","SG9999015952.SGD","IE00BMCWC346.EUR","00867","SG9999015945.SGD","BK1593","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","BK1191","IE00BYV24P56.USD","SG9999004220.SGD","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651161179","title":"英硅智能(03696.HK)与康哲药业(00867.HK)达成一项中枢神经系统领域药物研发战略新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651161179","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651161179?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:03","pubTimestamp":1783901028,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BVYPNQ40.USD","00867","SG9999015952.SGD","SG9999015945.SGD","BK1593","IE00BMCWC346.EUR","SG9999015978.USD","IE00BYV24P56.USD","SG9999015986.USD","BK1141","LU2488822045.USD","SG9999004220.SGD","IE00BVYPNP33.GBP","BK1191","03696","IE00BGHQDM52.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180152232","title":"康哲药业6月股份变动月报：总股本维持2,439,528,512股","url":"https://stock-news.laohu8.com/highlight/detail?id=1180152232","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180152232?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:27","pubTimestamp":1782984457,"startTime":"0","endTime":"0","summary":"2026年7月2日，康哲药业公布2026年6月股份变动月报。公告显示，公司法定及注册股本无变化，法定/注册总股本维持为100,000,000美元，对应20,000,000,000股普通股。截至2026年6月30日，普通股已发行股份由上月底的2,438,508,512股减至2,433,131,512股，减少5,377,000股。康哲药业在报告中确认符合香港联合交易所有限公司有关公众持股量的相应规定，所有股份回购均依据相关上市规则和适用法律规范执行。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cms.net.cn","stockEarnings":[{"period":"1week","weight":-0.0213},{"period":"1month","weight":-0.0621},{"period":"3month","weight":0.0578},{"period":"6month","weight":-0.1366},{"period":"1year","weight":-0.1741},{"period":"ytd","weight":-0.1165}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0247},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.0211},{"period":"1year","weight":-0.0051},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康哲药业控股有限公司是一家主要从事药品生产、营销、推广及销售业务的投资控股公司。该公司的产品包括波依定、优思弗、施图伦滴眼液、喜辽妥、艾蓓尔产品系列及Vmonalisa莫娜丽莎等。其主要在售产品覆盖心脑血管、消化、眼科、皮肤科及医美领域。该公司主要在中国国内和海外市场销售其产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.010937},{"month":2,"riseRate":0.6,"avgChangeRate":0.034686},{"month":3,"riseRate":0.4375,"avgChangeRate":-0.007408},{"month":4,"riseRate":0.5,"avgChangeRate":0.025614},{"month":5,"riseRate":0.4375,"avgChangeRate":-0.000084},{"month":6,"riseRate":0.625,"avgChangeRate":0.003749},{"month":7,"riseRate":0.5625,"avgChangeRate":0.001831},{"month":8,"riseRate":0.375,"avgChangeRate":0.017711},{"month":9,"riseRate":0.4375,"avgChangeRate":0.004621},{"month":10,"riseRate":0.5,"avgChangeRate":0.008358},{"month":11,"riseRate":0.5625,"avgChangeRate":0.054305},{"month":12,"riseRate":0.5625,"avgChangeRate":0.034382}],"exchange":"SEHK","name":"康哲药业","nameEN":"CMS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康哲药业(00867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康哲药业,00867,康哲药业股票,康哲药业股票老虎,康哲药业股票老虎国际,康哲药业行情,康哲药业股票行情,康哲药业股价,康哲药业股市,康哲药业股票价格,康哲药业股票交易,康哲药业股票购买,康哲药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康哲药业(00867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}